Belatacept is a medication that helps prevent organ rejection in kidney transplant patients. It works by suppressing the immune system to reduce the risk of the body attacking the transplanted kidney. It is specifically used to treat patients who have developed antibodies against their donor kidney, even when they don’t show obvious symptoms of rejection.

Tacrolimus is a commonly used anti-rejection medication that also works by suppressing the immune system. It helps prevent the body from rejecting the transplanted kidney by controlling the immune system’s response. It is considered a standard treatment option for kidney transplant recipients and is often used in combination with other medications to prevent organ rejection.

Both medications are used as part of a standard care regimen for kidney transplant patients who show signs of developing antibodies against their donor organ, even before obvious rejection symptoms appear.

Kidney Transplant Rejection – A condition where the recipient’s immune system recognizes the transplanted kidney as foreign and attacks it. The process can develop slowly over time (chronic rejection) or occur rapidly (acute rejection). The immune system creates antibodies against the donor kidney, leading to inflammation and potential damage to the transplanted organ. This condition can cause the transplanted kidney to function less effectively over time. The body produces specific antibodies called donor-specific antibodies (DSA) that target the transplanted kidney’s tissues.

Antibody-Mediated Rejection (ABMR) – A specific type of transplant rejection where antibodies produced by the recipient’s immune system attack the blood vessels of the transplanted kidney. This condition can develop without immediate symptoms (subclinical ABMR) or with clear clinical signs. The process involves the formation of antibodies that specifically target the donor organ’s tissues. These antibodies can cause inflammation and damage to the blood vessels within the transplanted kidney.